Targeted portfolio

A unique portfolio of high quality and difficult-to-make pharmaceutical products fuels our targeted growth strategy. Alvogen has over 200 strategically selected pharmaceutical projects in development and registrations and over 350 marketed products.



Who we are

Alvogen is a global, privately owned pharmaceutical company focused on developing, manufacturing and selling generic, brand, OTC and biosimilar products around the world. The company has commercial operations in 35 countries with 2,800 employees.



Alvogen obtains first approval for glatiramer acetate 40 mg/mL in Europe

Alvogen today announced the successful closure of the decentralized procedure for RemurelTM (glatiramer acetate) 40 mg/mL, the first generic equivalent of CopaxoneTM 40 mg/mL in Europe.

Read More

Meet management

Leadership team

Alvogen’s leadership team is dedicated to fostering a dynamic change-driven culture committed to meeting the needs of our customers. Our organizational structure is lean and flexible, driving quick and effective decision making and thus enabling the company to bring new generic products quickly and safely to market.

Meet management